Short‑ and long‑term treatment with angiotensin‑converting enzyme inhibitors or calcium channel blockers for the prevention of diabetic nephropathy progression: A meta‑analysis

Liang,Jialang; Lan,Jiarong; Tang,Qizhi; Ling,Wenjing; Li,Min

doi:10.3892/etm.2020.9446

Short‑ and long‑term treatment with angiotensin‑converting enzyme inhibitors or calcium channel blockers for the prevention of diabetic nephropathy progression: A meta‑analysis

Authors:
- Jialang Liang
- Jiarong Lan
- Qizhi Tang
- Wenjing Ling
- Min Li
View Affiliations

Affiliations: Endocrinology Department, Integrated Traditional Chinese and Western Medicine Hospital of Guangdong Province, Foshan, Guangdong 528200, P.R. China, Nephrology Department, Huzhou Hospital of Traditional Chinese Medicine Affiliated Zhejiang University of Traditional Chinese Medicine, Huzhou, Zhejiang 313000, P.R. China, Emergency Department, Integrated Traditional Chinese and Western Medicine Hospital of Guangdong Province, Foshan, Guangdong 528200, P.R. China, Endocrinology Department, Huzhou Hospital of Traditional Chinese Medicine Affiliated Zhejiang University of Traditional Chinese Medicine, Huzhou, Zhejiang 313000, P.R. China
Published online on: November 4, 2020 https://doi.org/10.3892/etm.2020.9446
Article Number: 14
Copyright: © Liang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Treatments with angiotensin‑converting enzyme (ACE) inhibitors or calcium channel blockers (CCBs) may delay the development of albuminuria in patients with early diabetic nephropathy. However, evidence in the literature has not been consistent. The present meta‑analysis aimed to compare the short‑ and long‑term therapeutic effects of ACE inhibitors and CCBs (when used separately) for preventing the progression of nephropathy in patients with diabetes mellitus. A comprehensive search of various databases was performed from inception until March 2015 for studies in the Chinese and English languages. Randomized controlled trials (RCTs) comparing the efficacy of ACE inhibitors with that of CCBs in patients with early diabetic nephropathy were considered. A total of 12 RCTs were included with a total of 947 patients. ACE inhibitors were indicated to be more effective in reducing the albumin excretion rate than CCBs after short‑term treatments (<6 months) [mean difference (MD), 32.35; 95% confidence interval (CI), 31.62‑33.07; P<0.00001]. There was no difference in serum creatinine values after treatment with either drug (MD, 8.7; 95% CI, ‑21.5‑38.91; P=0.57). Data from six studies were used to compare long‑term treatment effects (≥1 year). In terms of progression to normoalbuminuria, a marginal difference was obtained between the two drugs with better outcomes with ACE inhibitors [odds ratio (OR), 0.70; 95% CI, 0.49‑1.00; P=0.05]. There was no statistically significant difference between ACE inhibitors and CCBs regarding the progression from microalbuminuria to macroalbuminuria (OR, 1.78; 95% CI, 0.82‑3.87; P=0.15). In conclusion, the present study indicated that the antiproteinuric efficacy of CCBs may be less than that of ACE inhibitors after short‑term treatment in patients with DN. However, both types of drugs are equally effective in reducing the progression of microalbuminuria to macroalbuminuria in the long term.

View Figures

View References

1	Wild S, Roglic G, Green A, Sicree R and King H: Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 27:1047–1053. 2004.PubMed/NCBI View Article : Google Scholar
2	American Diabetes Association. Standards of medical care in diabetes - 2011. Diabetes Care. 34 (Suppl 1):S11–S61. 2011.PubMed/NCBI View Article : Google Scholar
3	Hajhosseiny R, Khavandi K, Jivraj N, Mashayekhi S, Goldsmith DJ and Malik RA: Have we reached the limits for the treatment of diabetic nephropathy? Expert Opin Investig Drugs. 23:511–522. 2014.PubMed/NCBI View Article : Google Scholar
4	Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 355:253–259. 2000.PubMed/NCBI
5	Hu R and Yang Z: Study on effect of the combined treatment of enalapril and amlodipine in elderly diabetic patients with hypertension. Diabetes New World. 24:6–7. 2014.(In Chinese).
6	Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. BMJ. 302:210–216. 1991.PubMed/NCBI View Article : Google Scholar
7	Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, O'Brien RC, Raffaele J and Tsalamandris C: Melbourne Diabetic Nephropathy Study Group. Long-term renoprotection by perindopril or nifedipine in non-hypertensive patients with Type 2 diabetes and microalbuminuria. Diabet Med. 21:1192–1199. 2004.PubMed/NCBI View Article : Google Scholar
8	Fogari R, Preti P, Zoppi A, Rinaldi A, Corradi L, Pasotti C, Poletti L, Marasi G, Derosa G, Mugellini A, et al: Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Am J Hypertens. 15:1042–1049. 2002.PubMed/NCBI View Article : Google Scholar
9	Luque Otero M and Martell Claros N: Study Investigators Group. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: A multicenter, randomized, double-blind, 24-week study. Clin Ther. 27:166–173. 2005.PubMed/NCBI View Article : Google Scholar
10	Higgins J and Green S: Cochrane Handbook for Systemic Reviews of Interventions. Version 5.1. The Cochrane Collaboration, 2011. urihttps://handbook-5-1.cochrane.orgsimplehttps://handbook-5-1.cochrane.org. Accessed June 1, 2020.
11	Higgins J, Altman D and Sterne J: Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (eds): Chapter 8: Assessing risk of bias in included studies. In: Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. urihttps://handbook-5-1.cochrane.org/chapter_8/8_assessing_risk_of_bias_in_included_studies.htmsimplehttps://handbook-5-1.cochrane.org/chapter_8/8_assessing_risk_of_bias_in_included_studies.htm.
12	Rachmani R, Lidar M, Brosh D, Levi Z and Ravid M: Oxidation of low-density lipoprotein in normotensive type 2 diabetic patients. Comparative effects of enalapril versus nifedipine: A randomized cross-over over study. Diabetes Res Clin Pract. 48:139–145. 2000.PubMed/NCBI View Article : Google Scholar
13	Fogari R, Zoppi A, Corradi L, Poletti L, Pasotti M, Fogari E and Mugellini A: Long-term effects of amlodipine versus fosinopril on microalbuminuria in elderly hypertensive patients with type 2 diabetes mellitus. Curr Ther Res Clin Exp. 61:163–173. 2000.
14	Shiba T, Inoue M, Tada H, Hayashi Y, Okuda Y, Fujita R, Makino F, Takahasi C, Kageyama S, Kitamura S, et al: Delapril versus manidipine in hypertensive therapy to halt the type-2-diabetes-mellitus-associated nephropathy. Diabetes Res Clin Pract. 47:97–104. 2000.PubMed/NCBI View Article : Google Scholar
15	Gao Z and Chang J: Effects of enalapril combined with Levamlodipine on type 2 diabetic nephropathy. J Med Theory Practice. 1:12–14. 2006.(In Chinese).
16	Chan JC, Ko GTC, Leung DHY, Cheung RC, Cheung MY, So WY, Swaminathan R, Nicholls MG, Critchley JA and Cockram CS: Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int. 57:590–600. 2000.PubMed/NCBI View Article : Google Scholar
17	Baba S: J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract. 54:191–201. 2001.PubMed/NCBI View Article : Google Scholar
18	Dalla Vestra M, Pozza G, Mosca A, Grazioli V, Lapolla A, Fioretto P and Crepaldi G: Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina). Diabetes Nutr Metab. 17:259–266. 2004.PubMed/NCBI
19	Jerums G, Allen TJ, Campbell DJ, Cooper ME, Gilbert RE, Hammond JJ, Raffaele J and Tsalamandris C: Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria. Am J Kidney Dis. 37:890–899. 2001.PubMed/NCBI View Article : Google Scholar
20	Wakahara S, Konoshita T, Mizuno S, Motomura M, Aoyama C, Makino Y, Kato N, Koni I and Miyamori I: Synergistic expression of angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 ratio. Endocrinology. 148:2453–2457. 2007.PubMed/NCBI View Article : Google Scholar
21	Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, et al: Japanese Society of Hypertension Committee: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 32:3–107. 2009.PubMed/NCBI
22	American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 26 (Suppl 1):S33–S50. 2003.PubMed/NCBI View Article : Google Scholar
23	Poortmans JR and Ouchinsky M: Glomerular filtration rate and albumin excretion after maximal exercise in aging sedentary and active men. J Gerontol A Biol Sci Med Sci. 61:1181–1185. 2006.PubMed/NCBI View Article : Google Scholar
24	Takahara A: Cilnidipine: A new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther. 27:124–139. 2009.PubMed/NCBI View Article : Google Scholar
25	Catterall WA: Structure and regulation of voltage-gated Ca²⁺ channels. Annu Rev Cell Dev Biol. 16:521–555. 2000.PubMed/NCBI View Article : Google Scholar
26	Ertel EA, Campbell KP, Harpold MM, Hofmann F, Mori Y, Perez-Reyes E, Schwartz A, Snutch TP, Tanabe T, Birnbaumer L, et al: Nomenclature of voltage-gated calcium channels. Neuron. 25:533–535. 2000.PubMed/NCBI View Article : Google Scholar
27	Agardh CD, Garcia-Puig J, Charbonnel B, Angelkort B and Barnett AH: Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens. 10:185–192. 1996.PubMed/NCBI
28	Ruggenenti P, Mosconi L, Bianchi L, Cortesi L, Campana M, Pagani G, Mecca G and Remuzzi G: Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients. Am J Kidney Dis. 24:753–761. 1994.PubMed/NCBI View Article : Google Scholar
29	Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M, Carraro A, Tonolo G, Fresu P, Cernigoi AM, et al: Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes. 45:216–222. 1996.PubMed/NCBI View Article : Google Scholar
30	Estacio RO, Jeffers BW, Gifford N and Schrier RW: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 23 (Suppl 2):B54–B64. 2000.PubMed/NCBI
31	Loutzenhiser R and Epstein M: Effects of calcium antagonists on renal hemodynamics. Am J Physiol. 249:F619–F629. 1985.PubMed/NCBI View Article : Google Scholar
32	Gansevoort RT, Apperloo AJ, Heeg JE, de Jong PE and de Zeeuw D: The antiproteinuric effect of antihypertensive agents in diabetic nephropathy. Arch Intern Med. 152:2137–2139. 1992.PubMed/NCBI
33	Ono T, Liu N, Kusano H, Nogaki F, Makino T, Muso E and Sasayama S: Broad antiproliferative effects of benidipine on cultured human mesangial cells in cell cycle phases. Am J Nephrol. 22:581–586. 2002.PubMed/NCBI View Article : Google Scholar
34	Fogari R, Zoppi A, Mugellini A, Lusardi P, Destro M and Corradi L: Effect of benazepril plus amlodipine vs benazepril alone on urinary albumin excretion in hypertensive patients with type ii diabetes and microalbuminuria. Clin Drug Investig. 13 (Suppl 1):50–55. 1997.
35	Shigihara T, Sato A, Hayashi K and Saruta T: Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes. Hypertens Res. 23:219–226. 2000.PubMed/NCBI View Article : Google Scholar
36	Zhao J: Therapy effect observation of Levamlodipine combined with Benazepril in the treatment of 22 cases of type 2 diabetic nephropathy with hypertension patients. Shandong Medicine: 53-54, 2010.
37	Noto H, Goto A, Tsujimoto T and Noda M: Effect of calcium channel blockers on incidence of diabetes: A meta-analysis. Diabetes Metab Syndr Obes. 6:257–261. 2013.PubMed/NCBI View Article : Google Scholar
38	Abe H, Mita T, Yamamoto R, Komiya K, Kawaguchi M, Sakurai Y, Shimizu T, Ohmura C, Ikeda F, Kawamori R, et al: Comparison of effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria in type 2 diabetics with hypertension: A pilot study. J Diabetes Investig. 4:202–205. 2013.PubMed/NCBI View Article : Google Scholar
39	Konoshita T, Makino Y, Kimura T, Fujii M, Morikawa N, Wakahara S, Arakawa K, Inoki I, Nakamura H and Miyamori I: Genomic Disease Outcome Consortium (G-DOC) Study Investigators. A crossover comparison of urinary albumin excretion as a new surrogate marker for cardiovascular disease among 4 types of calcium channel blockers. Int J Cardiol. 166:448–452. 2013.PubMed/NCBI View Article : Google Scholar